An electronic version of our annual report is posted under the financial reports section of our website.
Top >
SemBioSys trades on the TSX, Toronto Stock Exchange, under the symbol SBS.
Top >
SemBioSys was incorporated as SemBioSys Genetics Inc. in 1994 and went public on December 6, 2004.
Top >
SemBioSys operates on a fiscal year ending December 31. The quarterly report periods end March 31, June 30, September 30, and December 31. For our most recent reports visit the financial reports section of our website.
Top >
For a complete list of SemBioSys' regulatory filings visit the SEDAR website at www.sedar.com.
Top >
As of December 31,2009, the directors and senior officers of SemBioSys, as a group, beneficially owned, controlled, or directed, directly or indirectly, 5.0% (3.5% fully diluted) of the issued and outstanding common shares.
Top >
The current share capital organization consists of common shares and first preferred shares. As of December 31, 2009 there are 40,653,592 common shares, 14,079,181 share purchase warrants and no first preferred shares issued and outstanding.
Top >
A warrant is a certificate allowing the holder the opportunity to buy a share in a company at a stated price over a specified period.
Top >
SemBioSys has not declared or paid any dividends on the common shares to date.
Top >
Computershare Investor Services
530 - 8th Avenue SW
Calgary, Alberta T2P 3S8
Telephone: 403.267.6864
Fax: 403.267.6529
Top >
Contact our transfer agent Computershare Investor Services of Calgary at 403.267.6821.
Top >
SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's technology platform allows for the production of pharmaceutical proteins in an easily scalable, low cost (in terms of both capital and COGS) manner. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AIMilano, a next generation cardiovascular drug. SemBioSys' associate company, Botaneco Specialty Ingredients Inc., is a supplier of specialty ingredients to the personal care and topical OTC and Rx markets.
Top >
Botaneco, an associate company of SemBioSys, unveiled its first commercial product Hydresia™ in October 2007 followed by the launch of Hydresia™ G2 in April 2008. Hydresia™ is a natural emulsifying system for use in a broad range of products in the personal care industry. See the personal care page or www.botaneco.ca for more information.
In 2004, SemBioSys entered into a funded agreement with Arcadia to develop high GLA-expressing safflower plant lines using a proprietary Arcadia gene. Arcadia is now responsible for the commercialization of high GLA safflower oil and expects to have commercial quantities available for sale in the first quarter of 2010. Under the terms of the agreement, SemBioSys is entitled to receive royalties from Arcadia on GLA-associated commercial product sales, as well as milestone payments.
Top >
Our broad array of products under development offers a continuous stream of milestone events. For up-to-date progress consult our quarterly operational and financial reports or sign up using our information request form to be added to our email contact list for timely news releases and development updates.
Top >
SemBioSys employs a team of over 30 individuals, primarily focused on research and development supported by intellectual property, business development and administrative personnel.
Top >
If you are a registered SemBioSys shareholder please contact our transfer agent Computershare Investor Services at 403.267.6864.
If you are not a registered shareholder it is typically best to contact your personal brokerage house or agent directly.
Top >